During the past decade, Summit Medical Group Cancer Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Summit Medical Group Cancer Center" are "Abiraterone Acetate" (1 trials), "Androgens" (1 trials), "Antineoplastic Agents" (1 trials), "Antineoplastic Agents, Hormonal" (1 trials) and "Cyclin-Dependent Kinase 4" (1 trials). Many other conditions were trialed in "Summit Medical Group Cancer Center" in a lesser frequency.

Most popular intervention types in "Summit Medical Group Cancer Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (1 trials), "Abiraterone" (1 trials), "Pelabresib" (1 trials), "Placebo" (1 trials) and "Placebo for Abemaciclib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Summit Medical Group Cancer Center" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Summit Medical Group Cancer Center". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Summit Medical Group Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Summit Medical Group Cancer Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".